Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indoco Sees Domestic And International Growth

As Company’s Overall Revenues Grow By 43% In Q1 FY22

Executive Summary

Indoco has seen double-digit growth in domestic and international markets in the first quarter of financial year 2022. Headquartered in Mumbai, Indoco has reported overall growth of almost 43% and an increase of 124.6% in its operating profit in Q1 FY22.

You may also be interested in...



Indoco’s US Business Grows After Azopt Rival Launch

India’s Indoco saw its international business grow after Teva launched the Indoco-manufactured and developed first US generic version of Novartis’ Azopt (brinzolamide) 1% solution. Though the company saw muted domestic growth, it aims to bolster its overall performance by launching 20 products a year by 2023.

US Bill Would Create Emergency API Stockpile

US representatives Abigail Spanberger and David McKinley have introduced bipartisan legislation to create an emergency supply of active ingredients used in vital generics and to incentivize domestic manufacturing of these ingredients. The move has garnered support from many industry leaders.

Glenmark Launches Tiotropium DPI In Spain

India’s Glenmark has announced the launch of Tavulus, its generic version of Boehringer Ingelheim’s Spiriva Handihaler, in Spain. The company is also looking to launch its tiotropium bromide dry powder inhaler in other key European markets. 

Topics

Related Companies

UsernamePublicRestriction

Register

GB151173

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel